Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab

Arthritis and Rheumatology

Volumn 68, Issue 9, 2016, Pages 2083-2089

  Fleischmann, Roy ^a   Connolly, Sean E ^b   Maldonado, Michael A ^b   Schiff, Michael ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; METHOTREXATE;

ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MULTIBIOMARKER DISEASE ACTIVITY TEST; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SIMPLIFIED DISEASE ACTIVITY INDEX;

EID: 84983541236     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39714     Document Type: Article

References (19)

1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
2. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.
3. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.
4. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57.
5. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
6. Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007;21:789–804.
7. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012;64:640–7.
8. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013;8:e60635.
9. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012;64:1794–803.
10. Bakker MF, Cavet G, Jacobs JW, Bijlsma JW, Haney DJ, Shen Y, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012;71:1692–7.
11. Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 2013;52:1202–7.
12. Hirata S, Li W, Defranoux N, Cavet G, Bolce R, Yamaoka K, et al. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: a retrospective observational study. Mod Rheumatol 2015;25:344–9.
13. Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. Rheumatol Int 2016;36:295–300.
14. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86–94.
15. Fleischmann R, Schiff M, Weinblatt ME, Maldonado M, Massarotti E, Yazici Y. Two-year results from the AMPLE trial: low disease activity and association between remission and changes in physical function and radiographic outcomes with subcutaneous abatacept or adalimumab [abstract]. Arthritis Rheum 2013;65 Suppl:476.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
17. Haney D, Cavet G, Durez P, Alten R, Burmester G, Tak P, et al. Correlation of a multi-biomarker disease activity response assessment to Disease Activity Score 28 (C-reactive protein) response assessment and OMERACT RAMRIS Scores in a placebo-controlled rheumatoid arthritis clinical trial with abatacept (ASSET) [abstract]. Arthritis Rheum 2012;64 Suppl:S913.
18. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34–40.
19. Yamaoka K, Kubo S, Li W, Sonomoto K, Hirata S, Sasso EH, et al. Effects of tofacitinib on leptin and other components of the multi-biomarker disease activity score in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2014;73: Suppl:507–8.